Development of a transdermal sumatriptan formulation with iontophoresis

Area of Science:

• Pharmacology and Drug Delivery
• Dermatology and Transdermal Therapeutics

Background:

• A previous transdermal sumatriptan iontophoretic formulation was withdrawn due to skin adverse effects from prolonged electrical application.
• There is a need for safer, rapid-acting transdermal sumatriptan delivery for patients who cannot tolerate oral medications.

Purpose of the Study:

• To investigate if short-duration, low-current iontophoresis can achieve therapeutic sumatriptan plasma concentrations.
• To establish a potentially safer transdermal sumatriptan delivery system.

Main Methods:

• Calculated target plasma concentration in rats based on human therapeutic levels and rat pharmacokinetics.
• Applied varying concentrations of sumatriptan gel (0.04-0.4%) with different current densities (0.05-0.2 mA/cm²) for short durations (0.5-2 hours).
• Monitored plasma sumatriptan concentrations over time in rats.

Main Results:

• The 0.2% and 0.4% sumatriptan formulations at 0.1 mA/cm² exceeded the target plasma concentration (0.94 μg/mL) within 1.5 and 1.0 hours, respectively.
• The 0.2% formulation at a higher current density (0.2 mA/cm²) achieved the target concentration within 0.5 hours and maintained it for 3 hours.
• Short-duration, low-current iontophoresis demonstrated effective sumatriptan delivery.

Conclusions:

• Short-duration, low-current iontophoresis is an effective method for achieving therapeutic sumatriptan plasma concentrations.
• This approach presents a safer transdermal alternative for patients with contraindications to oral sumatriptan.
• Further development could lead to a reduced-risk treatment option for migraine patients.